Highlights Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
23.02 ^USD	+7.92%		+22.32%	-1.41%

Jun. 05	Certain Restricted Stock Units of Akero Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2024.	CI
Jun. 05	Certain Stock Options of Akero Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2024.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027	May. 10	MT
Akero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	Mar. 07	CI
Health Care Down on Growth Doubts -- Health Care Roundup	Mar. 04	DJ
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell as Traders Hope for Clues to Timing of Rate Cuts	Mar. 04	MT
Akero's lead drug helps improve scarring in fatty liver disease patients	Mar. 04	RE
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study	Mar. 04	CI
Akero Therapeutics' Q4 Loss Widens; Cash Expected to Fund Operations Into 2026	Feb. 29	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program	Dec. 18	CI
Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins	23-10-10	CI
Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH	23-10-09	CI
Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology	23-10-04	CI
Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023	23-08-28	CI
Akero Therapeutics' Shares Gain Nearly 5% After Reporting Narrower Q2 Loss; Efruxifermin in Phase 2 Clinical Development	23-08-11	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Akero says NASH drug shown to reduce liver fat by 65% in some patients	23-06-05	RE
Akero's NASH drug reduces liver fat by 65% in some patients	23-06-05	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Highlights

Filters